CDK 4/6 Inhibitors: Personalizing Treatment Choices and Optimizing Multidisciplinary Care

Recorded: March 1, 2023.


  • Introduction by Session Chair – Dr Maryam Lustberg
  • CDK4/6 inhibition in HR+ MBC: Current Standard and Emerging Challenges - Dr Paolo Tarantino
  • CDK4/6 Inhibitors: Toxicity Considerations - Dr Hope Rugo
  • What Is Important Today? Reassessment of Goals – and Acceptance of Side Effects - Is Needed in Shared Decision Making - Dr Kelly Shanahan (Patient Partner)
  • Case Study & Panel Discussion



  • To improve the understanding of clinicians in identifying which CDK 4/6 treatment to choose in taking a shared decision approach
  • The patient experience of targeted therapy toxicities and how it impacts quality of life, adherence, and disease outcomes
  • Identify innovative strategies to optimally manage related toxicities with CDK4/6 inhibitors in patients with breast cancer


Learner Outcomes:

  • How to make personalized treatment decisions for patients with hormone receptor positive breast cancer who are candidates for CDK 4/6 inhibitors
  • How to improve supportive care strategies for patients with breast cancer who are undergoing targeted therapy
  • Address in knowledge in management and how to best deliver multi D care for cancer survivors of all stages.

This webinar is made possible by an unrestricted educational grant provided by Pfizer.

Course Details

Make sure to login at the top-right to view the video linked below
© Copyright 2023 | All Rights Reserved Worldwide  |  Privacy Notice